Evidence map›Paper›PMID 25874926›Full record

ReviewMarine drugs2015

Fucoidan and cancer: a multifunctional molecule with anti-tumor potential.

Farzaneh Atashrazm, Ray M Lowenthal, Gregory M Woods, Adele F Holloway, Joanne L Dickinson

Open access · goldAbstract readReview
In one paragraph

Review in Marine drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed
42.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 339 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Enzymatic Hydrolysates fromMarine drugs · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Fucoidan in cancer therapy: from biomedical application to medicinal chemistry approach.Journal of materials science. Materials in medicine · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Farzaneh AtashrazmMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia. Farzaneh.atashrazm@utas.edu.au.
Ray M LowenthalMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia. R.M.Lowenthal@utas.edu.au.
Gregory M WoodsMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia. G.M.Woods@utas.edu.au.
Adele F HollowaySchool of Medicine, University of Tasmania, Hobart, Tasmania 7000, Australia. A.F.Holloway@utas.edu.au.
Joanne L DickinsonMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia. Jo.Dickinson@utas.edu.au.
University of Tasmania · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a wide variety of cancer types yet, all share some common cellular and molecular behaviors. Most of the chemotherapeutic agents used in cancer treatment are designed to target common deregulated mechanisms within cancer cells. Many healthy tissues are also affected by the cytotoxic effects of these chemical agents. Fucoidan, a natural component of brown seaweed, has anti-cancer activity against various cancer types by targeting key apoptotic molecules. It also has beneficial effects as it can protect against toxicity associated with chemotherapeutic agents and radiation. Thus the synergistic effect of fucoidan with current anti-cancer agents is of considerable interest. This review discusses the mechanisms by which fucoidan retards tumor development, eradicates tumor cells and synergizes with anti-cancer chemotherapeutic agents. Challenges to the development of fucoidan as an anti-cancer agent will also be discussed.

Indexed as

Models, BiologicalAngiogenesis InhibitorsAnimalsAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell Transformation, NeoplasticDrug Evaluation, PreclinicalDrugs, InvestigationalFunctional FoodHumansMAP Kinase Signaling SystemNeoplasm MetastasisNeoplasmsPhaeophyceaePolysaccharidesAngiogenesis InhibitorsAntineoplastic Agents, PhytogenicDrugs, InvestigationalfucoidanPolysaccharides

Identifiers

PMID25874926
PMCPMC4413214
OpenAlexW2014424662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.